my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-12-2008: BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed. Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Official List and to trading on the London Stock Exchange.
BTG confirms that Rolf Soderstrom, Finance Director of Protherics PLC, has joined the board of BTG as Chief Financial Officer and Christine Soden, the current Chief Financial Officer of BTG, has moved to the role of Chief Operating Officer.
“We are delighted to have completed this merger with Protherics, which gives us the platform to build a leading specialty pharmaceuticals business,” commented Louise Makin, BTG’s Chief Executive Officer. “Initial integration activities will focus on prioritising programmes in the development pipeline and rationalising operations to achieve the planned synergies and cost savings. We will provide an update on progress in due course.”
Watchlist
This is where you can add this news to your personal favourites
BTG plc: Completion of the Acquisition of Protherics PLC
BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed. Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Offici ... more
BTG licenses novel anticancer compound to Onyx Pharmaceuticals
BTG plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG’s novel anticancer compound, BGC 945. Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payment ... more
BTG plc: Tolerx initiates dosing of otelixizumab in a phase III clinical trial in type 1 diabetes
BTG plc notes the announcement by Tolerx, Inc. that it has initiated a pivotal phase III clinical trial of otelixizumab (TRX4) in patients with new onset type 1 diabetes. Initiation of the DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes) triggers a milesto ... more
BTG plc: Completion of the Acquisition of Protherics PLC
BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed. Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Offici ... more
European expert consortium combines forces to develop a novel pandemic influenza vaccine
A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund t ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
